DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Schwaab J, Knut M, Haferlach C, Metzgeroth G, Horny HP, Chase A. et al.
Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.
Ann Hematol 2015;
94: 233-8
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.